Refer this article to a friend :
AMAG Pharmaceuticals, Inc. Announces Presentation of Positive Results from Phase III Studies of Ferumoxytol as an Intravenous Iron Replacement Therapy in Kidney Transplant Recipients at the American Transplant Congress